BioSpace News Archive

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on AR101, oral immunotherapy and peanut allergy at the American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting, taking place November 15-19, 2018,

Company joins forces with nonprofit to expand K-12 STEM education

Clinical trials are a vital part of the research process, and for many kids with cancer, they are their best hope for a cure.

Grant to help address the pressing need of reducing the burden of tuberculosis (TB) in resource-poor settings

All quotes for attribution to National Kidney Foundation (NKF).

Enviro-Serv, Inc. (OTCBB: EVSV) has traditionally followed the business model for pest control service delivery on both commercial and government markets.

Psychiatry Northwest, LLC, one of the fastest growing transcranial magnetic stimulation (TMS) practices in the Pacific Northwest, announced today that it is offering BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) treatment to patients suffering from Obsessive-Compulsive Disorder (OCD) in its TMS Washington facility.

Specialty pharmaceutical company iX Biopharma (“iX Biopharma” or “the Group”) will be presenting the positive results from the Phase 2 clinical KET010 study for Wafermine.

Dr. U Devices, maker of Dr.UGraft Revolution Hair Transplant Systems, proudly announced today that it has now formed a worldwide partnership with Mamba Instruments and its founder, Dr. Roberto Trivellini, South America’s preeminent hair restoration surgeon.

By any measure, the Wind River Experimental Forest is a remote area. Yet two teams of ecologists managed to meet up and collaborate in their efforts to study the federally threatened Steelhead Trout species (Oncorhynchus mykiss) and map the long-term overall health of the aquatic system.